देरी से भुगतान और खातों में देनदारी (A/R)
Definition
The Mechanism: Manual follow-up on unpaid invoices and insurance claims delays cash collection. Labs without real-time tracking systems cannot quickly identify delayed payments or pursue claim denials. This extends Accounts Receivable (A/R) cycles, locking working capital.
Key Findings
- Financial Impact: LOGIC Evidence: Average healthcare A/R cycle in India: 45-75 days. For a lab with ₹10 lakhs monthly billing, 30-45 day reduction = ₹3,00,000-₹4,50,000 freed annually; also estimated 1-2% interest/opportunity cost on delayed receivables.
- Frequency: Ongoing (monthly/quarterly)
- Root Cause: Manual claim follow-up, lack of real-time tracking, slow insurance reimbursement verification
Why This Matters
The Pitch: Indian labs experience 30-60+ day A/R cycles due to manual claims follow-up. Automated real-time tracking and denial management systems reduce collection time by 15-25%, freeing up ₹1,00,000+ in working capital per 100 daily tests.
Affected Stakeholders
Billing coordinators, Collections staff, Finance managers
Deep Analysis (Premium)
Financial Impact
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Current Workarounds
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Get Solutions for This Problem
Full report with actionable solutions
- Solutions for this specific pain
- Solutions for all 15 industry pains
- Where to find first clients
- Pricing & launch costs
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
बिल न भेजे गए सेवाएं और चालान त्रुटियाँ
मैनुअल बिलिंग से कर्मचारी समय की बर्बादी
GST ई-इनवॉयसिंग और ITC समरूपता विफलता
गलत बिलिंग से ग्राहक प्रतिपूरक और वापसी
बहु-राज्य पर्यावरण शुल्क अनुपालन असंगति (Multi-State Fee Compliance Mismatch)
जैव-चिकित्सा अपशिष्ट प्रबंधन अनुमोदन प्रसंस्करण लागत (Biomedical Waste Authorization Cost Overrun)
Request Deep Analysis
🇮🇳 Be first to access this market's intelligence